Loading organizations...
§ Private Profile · Lebanon, NH, USA
Custom affinity purification solutions & AVIPure™ resins for biopharmaceutical manufacturing, purifying complex biologics like gene therapies.
Avitide is a biotechnology company based in Lebanon, New Hampshire, that discovers, develops, and manufactures custom affinity purification solutions for the global biopharmaceutical manufacturing industry. The organization provides proprietary chromatography technologies that enable drug developers to efficiently isolate complex biologics, including bispecific antibodies, recombinant proteins, gene therapies, and cell-based therapies. Operating as a business-to-business bioprocessing provider, the enterprise scaled its operations to approximately 35 employees while generating up to $7.4 million in annual revenue. The company raised over $50 million in venture capital funding from notable institutional investors, including Polaris Partners and OrbiMed, to advance its ligand discovery platform. Following this growth, the business was acquired by Repligen Corporation in September 2021 for a total valuation of approximately $275 million. Avitide was founded in 2012 by Kevin Isett, Warren Kett, Tillman Gerngross, and Errik Anderson.
Avitide has raised $38.0M across 4 funding rounds.
Avitide has raised $38.0M in total across 4 funding rounds.
Avitide is a biotechnology company that develops proprietary AVIPure™ affinity resins for biopharmaceutical purification, enabling efficient separation of target molecules like enzymes, antibodies, vaccines, growth factors, and gene therapies from impurities.[1][2][3][4] It serves biopharma developers across discovery, preclinical, clinical, and commercial stages, solving purification challenges such as removing truncations, aggregates, and misfolded proteins to improve purity, yield, stability, and process economics.[2][3][4] Founded in 2012 in Lebanon, New Hampshire, Avitide was acquired by Repligen in September 2021, accelerating its impact on next-generation biotherapeutics potentially reaching over 250 million patients worldwide.[1][2]
The company's platform leverages extreme ligand diversity (over 1E14 variants across 40+ scaffolds) for customized solutions, supporting scalable GMP manufacturing under ISO 9001:2015 certification.[2][3] This has driven growth through partnerships derisking novel modalities like cell/gene therapies and enabling continuous processing.[4]
Avitide was co-founded in 2012 by Kevin Isett, PhD (CEO), with deep experience in high-throughput bioprocessing from Adimab and over a decade at Merck in biologics and vaccines R&D, and Warren Kett, PhD (CSO), a Dartmouth researcher and co-founder of Glycan Biosciences (formerly GlycoFi, acquired by Merck).[1][6] The idea emerged from their expertise in addressing bioprocessing bottlenecks, pioneering affinity ligands selective for products over impurities—a gap in legacy technologies.[3]
Early traction included developing solutions for diverse molecules, culminating in milestones like the 2021 AVIPure-COV2S resin for COVID-19 vaccine purification.[1] The 2021 acquisition by Repligen marked a pivotal evolution, integrating Avitide's platform into a larger bioprocessing leader while retaining its Lebanon, NH base and entrepreneurial culture.[1][2]
Avitide stands out in biopharma purification through:
Key team expertise, including 20+ years from Novo Nordisk/GE in separations (Karol Lacki, PhD), bolsters developer experience.[6]
Avitide rides the surge in complex biologics like cell/gene therapies, bispecific antibodies, and viral vaccines, where traditional purification fails on impurities and scale.[1][4] Timing aligns with post-COVID bioprocessing demands for speed and continuity, as seen in its 2021 COVID resin and Repligen integration amid a chromatography market projected to grow from $561M in 2023 to $1.2B by 2033.[1]
Market forces favoring Avitide include rising novel modality pipelines, CAPEX pressures for multi-product facilities, and shifts to continuous manufacturing—its platform lowers COGS, leverages existing infrastructure, and derisks CDMO transitions.[2][4] It influences the ecosystem by enabling faster, cheaper access to therapies, expanding IP around biologics, and setting standards for impurity-specific affinity tech.[3][4]
Avitide's Repligen backing positions it to dominate affinity purification for emerging modalities like next-gen gene therapies and continuous bioprocessing, with trends in AI-driven ligand design and supply chain resilience amplifying its edge.[2][3] Expect expanded partnerships, new ligands for multi-specifics/ADCs, and global facility scaling to capture chromatography market growth.
As a post-acquisition powerhouse, Avitide evolves from innovator to indispensable enabler, directly fueling biopharma's race to impact 250M+ patients through superior purity and efficiency.[2]
Avitide has raised $38.0M across 4 funding rounds. Most recently, it raised $12.0M Series E in June 2017.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2017 | $12M Series E | — | Borealis Ventures, Flagship Ventures, InterWest, Vivo Capital, Wildcat Ventures | Announced |
| Sep 12, 2016 | $17M Venture Round | Novartis | — | Announced |
| Aug 1, 2015 | $8M Series C | — | Borealis Ventures, Flagship Ventures, InterWest, OrbiMed, Polaris Partners, SV Health Investors, Vivo Capital, Wildcat Ventures, N5 Capital, Claudio Nessi, Terrance McGuire, SV Health Investors | Announced |
| Mar 1, 2013 | $1M Series A | — | Borealis Ventures, Flagship Ventures, InterWest, OrbiMed, Polaris Partners, SV Health Investors, Vivo Capital, Wildcat Ventures | Announced |
Avitide has raised $38.0M in total across 4 funding rounds.
Avitide's investors include Borealis Ventures, Flagship Ventures, InterWest, Vivo Capital, Wildcat Ventures, Novartis, OrbiMed, Polaris Partners, SV Health Investors, N5 Capital, Claudio Nessi, Terrance McGuire.